ArticleNature communications2022

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.

Simeng Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.